肝门部胆管癌机器人手术的初步实施与结局:单中心经验
该单中心回顾性研究分析了2013年至2026年间76例行根治性肝门部胆管癌切除的患者,其中66例开腹手术、10例机器人手术。机器人组R0切除率90.0%、开腹组78.8%,机器人组教科书结局(TO)达50.0%高于开腹组36.3%但差异无统计学意义(P=0.415),主要并发症两组分别为30.0%和25.7%(P=0.780),机器人组无90天死亡。结论认为在高度选择的患者中机器人手术可行且可安全实施。
要点
- 机器人组R0切除率90.0%,开腹组78.8%,淋巴结清扫两组无显著差异。
- 机器人组TO达标率50.0% vs 开腹组36.3%,差异无统计学意义(P=0.415)。
- 机器人组主要并发症30.0%,开腹组25.7%(P=0.780),机器人组无90天死亡。
核心结论
- 肝门部胆管癌机器人手术在高度选择患者中可行,并可在机构验证后安全实施。
- 早期经验显示围术期结局可接受,但需更大样本和长期随访进一步评估其临床效用。
研究设计与样本
- 单中心回顾性分析,纳入2013年1月至2026年1月间76例行根治性意图切除的肝门部胆管癌患者。
- 66例行开腹手术,10例行机器人切除;机器人手术在机构积累开腹和复杂机器人肝胆手术经验后引入。
- 比较两组围术期结局、肿瘤学参数和教科书结局(TO)达成情况。
主要发现
- 机器人组R0切除率90.0%,开腹组78.8%;淋巴结获取两组无显著差异。
- 机器人组TO达成率50.0%,开腹组36.3%,差异无统计学意义(P=0.415)。
- 主要并发症机器人组30.0%,开腹组25.7%(P=0.780);机器人组无90天死亡。
- 尽管采用微创方式,两组住院时间相似。
关键数值与推荐
- R0切除:机器人组90.0%,开腹组78.8%。
- TO达成:机器人组50.0%,开腹组36.3%(P=0.415)。
- 主要并发症:机器人组30.0%,开腹组25.7%(P=0.780)。
- 90天死亡:机器人组无。
临床怎么用
- 在具有丰富开腹和复杂机器人肝胆手术经验的机构中,可对高度选择的肝门部胆管癌患者谨慎开展机器人手术。
- 早期实施阶段应关注病例选择,并持续评估围术期和肿瘤学结局。
局限性
- 单中心回顾性研究,样本量小(机器人组仅10例),可能存在选择偏倚。
- 缺乏长期随访数据,无法评估远期肿瘤学结局。
- 早期实施阶段经验有限,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robotic surgery for perihilar cholangiocarcinoma (pCCA) remains controversial owing to concerns regarding its technical feasibility and oncological adequacy. This study evaluated the early clinical outcomes of robotic surgery for pCCA during the institutional transition from open to robotic surgery. METHODS: We retrospectively analyzed 76 patients who underwent curative-intent resection for pCCA between January 2013 and January 2026. Of these patients, 66 underwent open surgery and 10 underwent robotic resection. Robotic surgery was introduced following extensive institutional experience with open and complex robotic hepatobiliary procedures. Perioperative outcomes, oncological parameters, and textbook outcome (TO) achievement were compared between the groups. RESULTS: R0 resection was achieved in 90.0% of robotic cases and 78.8% of open cases, and lymph node retrieval did not differ significantly between the groups. A higher proportion of patients in the robotic group attained TO (50.0% vs. 36.3%), although this trend did not reach statistical significance (P = 0.415). Major complications occurred in 30.0% of robotic cases and 25.7% of open cases (P = 0.780), and no 90-day mortality occurred in the robotic group. The length of hospital stay was similar despite the minimally invasive approach. CONCLUSIONS: Robotic surgery for pCCA is feasible and can be safely implemented following institutional validation in highly selected patients during the early implementation phase. While our early experience demonstrates acceptable perioperative outcomes, additional studies with larger cohorts and long-term follow-up are required to further evaluate the clinical utility and outcomes of robotic surgery and to define its role in pCCA.
引用
- Jang EJ, Kim KW. Transitioning to the robotic era for perihilar cholangiocarcinoma: initial implementation and outcomes in a single center. Surg Endosc. 2026. PMID: 42786312. doi:10.1007/s00464-026-13403-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。